Connect Biopharma (CNTB) announced that the independent Data Monitoring Committee overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the company’s next-generation anti-interleukin-4-receptor alpha antibody, has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma director buys $4.0M in common stock
- Buy Rating on CNTB Driven by Rademikibart’s Rapid Lung Function Gains, COPD Differentiation, and Strengthened Cash Runway
- Buy Rating on CNTB: Fast-Acting Rademikibart Data Underscore Differentiation and Long-Term Respiratory Opportunity
- Connect Biopharma Highlights Positive Rademikibart Respiratory Trial Results
- Connect Biopharma announces results from rademikibart study